ADVFN - Advanced Financial Network.
HOME» NYSE » S » SGP Stock Price » SGP Stock News

Schering Plough Share News

 Schering-plough Corp. Stock Price
SGP Stock Price
 Schering-plough Corp. Stock Chart
SGP Stock Chart
 Schering-plough Corp. Stock News
SGP Stock News
 Schering-plough Corp. Company Information
SGP Company Information
 Schering-plough Corp. Stock Trades
SGP Stock Trades

Schering-Plough 3Q Earnings Down 16% On Charges

DOW JONES NEWSWIRES Schering-Plough Corp.'s (SGP) third-quarter profit fell 16% on increased charges while the company saw a 5% drop in sales of the cholesterol drugs it sells jointly with merger partner Merck & Co. (MRK) The companies' joint venture has been under pressure since an early 2008 study raised questions about the safety and effectiveness of Vytorin and Zetia. Meanwhile, the $49 billion Schering-Merck deal announced in March remains on track to close in the current quarter. Merck is buying Schering to diversify its pipeline, a move sparked by continuing generic competition, pricing pressure and difficulty in bringing new drugs to market. Schering-Plough's earnings dropped to $515 million, or 29 cents a share, from $677 million, or 39 cents a share, a year earlier. Excluding acquisition-related charges and other impacts, earnings rose to 40 cents from 39 cents. Net sales fell 1.7% to $4.5 billion, reflecting a 6-percentage-point hit from currency changes. Analysts surveyed by Thomson Reuters were expecting earnings, excluding items, of 40 cents a share on revenue of $4.47 billion. Gross margin fell to 61.8% from 62% on the charges, and fell 1 percentage point excluding them on the currency chanages. Three-fifths of the cholesterol venture's sales drop was due to the foreign-exchange fluctuations. Sales slid 10% in the U.S. Among Schering-Plough's non-cholesterol treatments, sales of arthritis drug Remicade rose 8%, or 18% excluding currency changes, while allergy treatment Nasonex saw a 3% increase, also held back by foreign exchange rates. Cancer drug Temodar grew 2%. Schering-Plough shares closed Wednesday at $29.01 and didn't trade premarket. The stock is up 70% this year. Merck is expected to report its results later Thursday. -By Mike Barris and Kevin Kingsbury, Dow Jones Newswires; 212-416-2330; mike.barris@dowjones.com

Stock News for Schering Plough (SGP)
DateTimeHeadline
11/03/200910:47:18Merck/Schering Cholesterol Drugs At Another Crossroads
11/02/200915:24:04FDA Says No To Application For Potential Lipitor/Zetia Combo
10/23/200904:20:25EU Clears Merck & Co To Buy Schering-Plough
10/22/200915:23:10US Drug Makers 3Q Helped By Cost Cuts, Major Product Sales
10/22/200910:23:05CORRECT: Schering-Plough 3Q Earnings Down 16% On Charges
10/22/200908:28:11Merck 3Q Net More Than Triples On Gain; Boosts View
10/22/200907:13:06Schering-Plough 3Q Earnings Down 16% On Charges

Schering Plough and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad